Project description
Novel drugs against cancer and inflammatory diseases
CXCR4 is a chemokine receptor implicated in several pathological conditions including cancer and viral infections. It is activated by CXCL12, which regulates cell adhesion to stroma and hematopoietic stem cell mobilisation, and also serves as a co-receptor for HIV entry into cells. The aim of the EU-funded EPI-X4Health project is to test the endogenous peptide EPI-X4 for its therapeutic potential against cancer and inflammatory diseases. EPI-X4 is a human serum albumin derivative previously identified by the scientific team to inhibit HIV. Researchers will screen new synthetic derivatives of EPI-X4 in animal models of disease.
Fields of science
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencesbiological sciencesbiochemistrybiomolecules
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesclinical medicineoncology
Programme(s)
Funding Scheme
ERC-POC - Proof of Concept GrantHost institution
89081 Ulm
Germany
See on map
Beneficiaries (3)
89081 Ulm
See on map
80686 Munchen
See on map
67081 Strasbourg
See on map